|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:alternativeTo
|
gptkb:atovaquone/proguanil
doxycycline
chloroquine
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
P01BC02
|
|
gptkbp:availableOn
|
gptkb:tablet
|
|
gptkbp:brand
|
gptkb:mefloquine
|
|
gptkbp:chemicalClass
|
quinoline methanol
|
|
gptkbp:contraindication
|
history of seizures
history of psychiatric disorders
|
|
gptkbp:developedBy
|
gptkb:F._Hoffmann-La_Roche
|
|
gptkbp:discontinued
|
some countries
|
|
gptkbp:eliminationHalfLife
|
2-4 weeks
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lariam
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:marketedAs
|
1989
|
|
gptkbp:mechanismOfAction
|
interferes with parasite DNA replication
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 3 months
patients with depression
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:sideEffect
|
nausea
dizziness
neuropsychiatric effects
vivid dreams
|
|
gptkbp:usedFor
|
malaria treatment
malaria prevention
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:mefloquine
|
|
gptkbp:bfsLayer
|
6
|